Drugs / GRT6019
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07479745 | Mar → Jun 2026 overdue | — | Grünenthal GmbH | Recruiting | No outcome recorded |
| Phase 1 | NCT07347548 | Jan → Jun 2026 overdue | Duchenne muscular dystrophy | Grünenthal GmbH | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07317063 | Nov 2025 → Jan 2026 | Duchenne muscular dystrophy | Grünenthal GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRT6019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07317063 ↗ |
| Route | Oral | “single oral dose of GRT6019” NCT07317063 ↗ |